Company website

As the CSO (Chief Scientific Officer) of Epigenomics, Kurt leads the biomedical research and development activities of the biotech company. Epigenomics develops diagnostic tests for illnesses that can be diagnosed or classified based on their DNA methylation patterns. By comparing DNA samples from healthy and sick individuals, Epigenomics has shown that different types of tumours carry tumour-specific DNA methylation patterns. Epigenomics also develops pharmacodiagnostic tests to see whether patients respond to a particular medication. In developing such tests, Epigenomics uses advanced data analysis techniques to deal with the hundreds of samples screened every day.